Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Martin Menter

Dermatology Dallas, TX Medical Doctor

NPI 1043268907 CMS profile 137563

3900 Junius St, Suite 145, Dallas, TX 75246

Open in the dashboard

General payments

$511,603

834 records reported · program years 2019–2023

Research payments

$11,566

Paid to them · 5 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,171,655 paid to institutions, not to them · program years 2019–2025

Through program year 2023, Martin Menter of Dallas, TX is reported in the CMS Open Payments database as having received $511,603 across 834 general payments and $11,566 in research payments paid to them. Separately, studies naming them as principal investigator received $3,171,655 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $36 2
2022 General $35,668 30
2021 General $112,463 188
2020 General $87,590 198
2020 Research $4,375 1
2019 General $275,846 416
2019 Research $7,191 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Menter
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Martin Menter were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Martin Menter Dermatology median Middle half National median
2019 $275,846 $454 $129–$1,240 $163
2020 $87,590 $235 $81–$756 $114
2021 $112,463 $377 $108–$1,108 $132
2022 $35,668 $514 $143–$1,391 $149
2023 $36 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Scientific Affairs, LLC $95,750 58 payments
  2. Lilly USA, LLC $95,466 128 payments
  3. AbbVie, Inc. $90,810 135 payments
  4. Sun Pharmaceutical Industries Inc. $53,635 73 payments
  5. Amgen Inc. $29,005 44 payments
  6. UCB, Inc. $22,637 29 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $21,704 42 payments
  8. Eli Lilly and Company $19,775 5 payments
  9. Celgene Corporation $19,038 31 payments
  10. Novartis Pharmaceuticals Corporation $17,030 86 payments
  11. Other $46,752 203 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $302,559 119 payments
  2. Consulting Fee $109,232 38 payments
  3. Travel and Lodging $36,128 88 payments
  4. Honoraria $30,760 12 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $16,300 5 payments
  6. Food and Beverage $16,220 567 payments
  7. Gift $264 1 payment
  8. Education $141 4 payments
Products named General payments · program years 2019–2023
  1. TALTZ $102,029 108 payments
  2. TREMFYA $100,727 115 payments
  3. ILUMYA $53,527 68 payments
  4. SKYRIZI $47,427 72 payments
  5. HUMIRA $43,802 90 payments
  6. Cimzia $22,691 26 payments
  7. SILIQ $21,608 32 payments
  8. Otezla Inflammation $18,740 33 payments
  9. Otezla Dermatology $12,863 9 payments
  10. COSENTYX $10,045 33 payments
  11. Other $38,872 283 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Novartis Pharmaceuticals Corporation $8,686 2 payments
  2. Eli Lilly and Company $1,453 2 payments
  3. Regeneron Pharmaceuticals, Inc. $1,426 1 payment

Records

839 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record